SUNNYVALE. Calif.. Nov. 6 /PRNewswire/ -- Pathwork Diagnostics a genomics-based diagnostics affiliate focused on oncology announced today that Virginia Commonwealth University School of care for has initiated an investigational study of the Pathwork(TM) Tissue of Origin Test. The new genomics-based test is designed to back up determine a tumor's origin so that tissue-specific management can begin. VCU's study makes it one of the first institutions in the country to evaluate this leading technology in patients who may have few remaining diagnostic options. The create from raw material of Origin evaluate is also the focus of two workshops and two poster presentations at the 12th Annual Meeting of the Association for Molecular Pathology this week (November 7-10. Los Angeles).
"Patient cases in which a tumor cannot be readily identified are a significant problem," said Catherine Dumur. Ph. D.. Director of Molecular Morphology Genomics for the Department of Pathology. VCU. "Such cases are time-consuming for physicians and anxiety-producing for patients and are a challenge to providing the most appropriate care for the patient. We are eager to see how this investigational new genomics-based test extends and complements traditional histopathological approaches."
There are an estimated 200,000 cancer patients each year in the United States who may acquire from additional diagnostic information to determine the create from raw material of origin for their cancer. National Comprehensive Cancer Network guidelines emphasize the importance of identifying the create from raw material of origin so that management specific to the primary cancer can mouth.
"We conceive of that in the future genomics data ordain change state a useful ancillary drive to pathologists to answer complex cancer questions in a clinical setting," said Carleton Garrett. M. D. Ph. D.. Director of the Tissue and Data Acquisition and Analysis core out at VCU. "Virginia Commonwealth University ordain continue to evaluate the use of such innovative technologies in order to verify that our cancer patients act to receive the beat possible care."
The Pathwork Tissue of Origin Test's proprietary analytics are designed to measure the expression of more than 1600 genes and compare a tumor's genetic "signature" against those of 15 known tissue types. The evaluate uses microarray technology which enables large numbers of genes to be evaluated at the same measure using the proven commercially available Affymetrix equip system. Up until now microarrays undergo been used primarily as research tools but presented challenges for use in clinical settings.
"Our unique processes undergo enabled us to beat the challenges of applying microarray technology for clinical use and create clinically useful diagnostic tests using microarray-based data," explained Pathwork President and C. E. O. Deborah J. Neff. "The microarray is a great platform because we can look at so many pieces of information simultaneously."
At this week's 12th Annual Meeting of the Association for Molecular Pathology. Pathwork Diagnostics will host a corporate workshop. "Diagnostic System to determine the Tissue of Origin in Poorly Differentiated or Undifferentiated Cancers Using Gene Expression," presented by Federico Monzon. M. D.. Methodist Hospital. Houston. TX; and Iris Schrijver. M. D.. Stanford University. Stanford. CA (Wednesday. November 7. 4-5 PM. Santa Monica Room).
A second Pathwork Diagnostics workshop. "Designing for IVDMIA. Gene Expression Profiling and Molecular Oncology," will act displace as move of the Affymetrix Corporate Workshop. It will be presented by C. Ted Rigl. Ph. D.. V. P. Product Development at Pathwork Diagnostics (Wednesday. November 7. 10 AM to noon. Olympic A Room).
The Tissue of Origin Test is the cerebrate of two poster presentations at the meeting: "Analytic performance of a microarray-based gene expression test to cause tissue of origin in uncertain primary cancers" will be presented by Catherine I. Dumur. Ph. D.. Virginia Commonwealth University. Richmond. VA (#ST01. Thursday. November 8. 2:30-4:30 PM. Constellation and Olympic Ballroom).
"Validation of a gene expression-based create from raw material of origin evaluate applied to poorly differentiated and undifferentiated cancers" will be presented by Federico Monzon. M. D.. Methodist Hospital. Houston. TX (#ST102. Friday. November 9. 1:00-3:00 PM. Constellation and Olympic Ballroom).
Virginia Commonwealth University is the largest university in Virginia and ranks among the top 100 universities in the country in sponsored research. Located on two downtown campuses in Richmond. VCU enrolls more than 31,000 students in nearly 200 award and degree programs in the arts sciences and humanities. Sixty-three of the programs are unique in Virginia many of them crossing the disciplines of VCU's 15 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center one of the nation's leading academic medical centers. For more see
Pathwork Diagnostics based in Sunnyvale. California develops and delivers genomics-based diagnostics that advance cancer care. The affiliate solves unmet clinical needs in oncology by using innovative technology to harness the power of genomics information and bear on it in a robust reproducible and reliable manner. Pathwork Diagnostics plans to deliver FDA-cleared microarray-based diagnostic tests for oncology to the clinical laboratory. The company's sign tests ordain be of Pathwork Diagnostics' proprietary analytics and a companion Pathchip(TM) microarray which runs on the proven Affymetrix equip system. The company's first evaluate -- the Pathwork(TM) Tissue of Origin Test -- is designed to be an aid in the diagnosis of the tissue of origin in patients with undifferentiated or poorly differentiated tumors or metastases.
Forex Groups - Tips on Trading
Related article:
http://www.biotechnologymarketnews.com/2007/11/virginia-common.html
comments | Add comment | Report as Spam
|